tbuckley/cabot-search huggingface dataset:
Real-world data confirms limited efficacy of dual anti-PD-1 and CTLA-4 immune checkpoint blockade in acral lentiginous melanoma
Authors: David X Zheng, Russell W Jenkins
Journal: British Journal of Dermatology (2024)

Journal Article Accepted manuscript Real-world data confirms limited efficacy of dual anti-PD-1 and CTLA-4 immune checkpoint blockade in acral lentiginous melanoma Get access David X Zheng, David X Zheng Mass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USABroad Institute of MIT and Harvard, Cambridge, MA, USA Correspondence: David X. Zheng, MD, Email:dxzheng@mgh.harvard.edu https://orcid.org/0000-0002-3351-023X Search for other works by this author on: Oxford Academic Google Scholar Russell W Jenkins Russell W Jenkins Mass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USABroad Institute of MIT and Harvard, Cambridge, MA, USA https://orcid.org/0000-0001-6110-2148 Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, ljae445, https://doi.org/10.1093/bjd/ljae445 Published: 15 November 2024 Article history Received: 06 November 2024 Accepted: 14 November 2024 Published: 15 November 2024
Building robust, proportionate, and timely approaches to regulation and evaluation of digital mental health technologies
Authors: Gareth Hopkin, Richard Branson, Paul Campbell, Holly Coole, Sophie Cooper, Francesca Edelmann, Grace Gatera, Jamie Morgan, Mark Salmon
Journal: The Lancet Digital Health (2024)

Demand for mental health services exceeds available resources globally, and access to diagnosis and evidence-based treatment is affected by long delays. Digital mental health technologies present an opportunity to reimagine the delivery of mental health support by providing innovative, effective, and tailored approaches that meet people's individual preferences and goals. These technologies also present new challenges, however, and efforts must be made to ensure they are safe and effective. The UK Medicines and Healthcare products Regulatory Agency and the National Institute for Health and Care Excellence have launched a partnership, funded by Wellcome, that explores regulation and evaluation of digital mental health technologies. This Viewpoint describes a series of key challenges across the regulatory and health technology assessment pathways and aims to facilitate discussions to ensure that approaches to regulation and evaluation are informed by patients, the public, and professionals working within mental health. We invite partners from across the mental health community to engage with, collaborate with, and provide scrutiny of this project to ensure it delivers the best possible outcomes.
Substantiation of trophoblast transport of maternal anti-SSA/Ro autoantibodies in fetuses with rapidly progressive cardiac injury: implications for neonatal Fc receptor blockade
Authors: Jill P Buyon, Philip M Carlucci, Bettina F Cuneo, Mala Masson, Peter Izmirly, Nalani Sachan, Justin S Brandt, Shilpi Mehta-Lee, Marc Halushka, Kristen Thomas, Melanie Fox, Colin Kl Phoon, Achiau Ludomirsky, Ranjini Srinivasan, Garrett Lam, Benjamin J Wainwright, Nicola Fraser, Robert Clancy
Journal: The Lancet Rheumatology (2024)
Overweight and obesity among Israeli adolescents and the risk for serious morbidity in early young adulthood: a nationwide retrospective cohort study
Authors: Yair Zloof, Maya Nitecki, Maya Simchoni, Ofek Adar, Avishai M Tsur, Estela Derazne, Dorit Tzur, Jacob Rotschield, Maya Braun, Orit Pinhas-Hamiel, Naomi Fliss Isakov, Hadar Milloh-Raz, Dan Nemet, Dror Dicker, Avi Moyal, Oded Scheuerman, Zivan Beer, Marius Braun, Arnon Afek, Hertzel C Gerstein, George David Batty, Gabriel Chodick, Gilad Twig
Journal: The Lancet Diabetes & Endocrinology (2024)
Expansion of Oropouche virus in non-endemic Brazilian regions: analysis of genomic characterisation and ecological drivers
Authors: Tiago Gräf, Edson Delatorre, Caroline do Nascimento Ferreira, Agata Rossi, Hellen Geremias Gatica Santos, Bianca Ribeiro Pizzato, Valdinete Nascimento, Victor Souza, Gustavo Barbosa de Lima, Filipe Zimmer Dezordi, Alexandre Freitas da Silva, Clarice Neuenschwander Lins de Morais, Ighor Arantes, Mariza Hoffmann Machado, Darcita Buerger Rovaris, Mayra Marinho Presibella, Nelson Fernando Quallio Marques, Emanuelle Gemin Pouzato, Jucelia Stadinicki, Rodrigo Ribeiro-Rodrigues, Thiago de Jesus Sousa, Andréa Cony Cavalcanti, Adriana Cardoso Camargo, Keilla Maria Paz E Silva, Mayara Matias de Oliveira Marques da Costa, Fernanda de Bruycker-Nogueira, Camila Zanluca, Ana Maria Bispo de Filippis, Claudia Nunes Duarte Dos Santos, Gabriel Luz Wallau, Gonzalo Bello, Felipe Gomes Naveca
Journal: The Lancet Infectious Diseases (2024)
Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial
Authors: Giovanni Randon, Sara Lonardi, Matteo Fassan, Federica Palermo, Stefano Tamberi, Elisa Giommoni, Carlotta Ceccon, Samantha Di Donato, Lorenzo Fornaro, Oronzo Brunetti, Ferdinando De Vita, Alessandro Bittoni, Claudio Chini, Andrea Spallanzani, Floriana Nappo, Valerie Bethaz, Antonia Strippoli, Tiziana Latiano, Giovanni Gerardo Cardellino, Francesco Giuliani, Federica Morano, Monica Niger, Alessandra Raimondi, Michele Prisciandaro, Chiara Carlotta Pircher, Carolina Sciortino, Silvia Marchesi, Silvio Ken Garattini, Giulia Airò, Rosalba Miceli, Maria Di Bartolomeo, Filippo Pietrantonio
Journal: The Lancet Oncology (2024)
Attitudes and perceptions of medical researchers towards the use of artificial intelligence chatbots in the scientific process: an international cross-sectional survey
Authors: Jeremy Y Ng, Sharleen G Maduranayagam, Nirekah Suthakar, Amy Li, Cynthia Lokker, Alfonso Iorio, R Brian Haynes, David Moher
Journal: The Lancet Digital Health (2024)

Chatbots are artificial intelligence (AI) programs designed to simulate conversations with humans that present opportunities and challenges in scientific research. Despite growing clarity from publishing organisations on the use of AI chatbots, researchers' perceptions remain less understood. In this international cross-sectional survey, we aimed to assess researchers' attitudes, familiarity, perceived benefits, and limitations related to AI chatbots. Our online survey was open from July 9 to Aug 11, 2023, with 61 560 corresponding authors identified from 122 323 articles indexed in PubMed. 2452 (4·0%) provided responses and 2165 (94·5%) of 2292 who met eligibility criteria completed the survey. 1161 (54·0%) of 2149 respondents were male and 959 (44·6%) were female. 1294 (60·5%) of 2138 respondents were familiar with AI chatbots, and 945 (44·5%) of 2125 had previously used AI chatbots in research. Only 244 (11·4%) of 2137 reported institutional training on AI tools, and 211 (9·9%) of 2131 noted institutional policies on AI chatbot use. Despite mixed opinions on the benefits, 1428 (69·7%) of 2048 expressed interest in further training. Although many valued AI chatbots for reducing administrative workload (1299 [66·9%] of 1941), there was insufficient understanding of the decision making process (1484 [77·2%] of 1923). Overall, this study highlights substantial interest in AI chatbots among researchers, but also points to the need for more formal training and clarity on their use.
Molecular Heterogeneity and Immune Infiltration Drive Clinical Outcomes in Upper Tract Urothelial Carcinoma
Authors: Kwanghee Kim, Syed M Alam, Fengshen Kuo, Ziyu Chen, Wesley Yip, Andrew B Katims, Carissa Chu, Andrew T Lenis, Wenhuo Hu, Gamze Gokturk Ozcan, Jie-Fu Chen, Sanaz Firouzi, Yuval Elhanati, Timothy N Clinton, Andreas Aulitzky, Nima Almassi, Yoich Fujii, Andrew T Tracey, Peter A Reisz, Sadna Budhu, Lynda Vuong, Jordan Eichholz, Hyung Jun Woo, Lucas Nogueira, Sizhi P Gao, Avigdor Scherz, David H Aggen, Jonathan E Rosenberg, Eugene J Pietzak, Venkatraman Seshan, Benjamin Greenbaum, Anton Becker, Oguz Akin, Gopa Iyer, Hikmat Al-Ahmadie, A Ari Hakimi, Taha Merghoub, David B Solit, Jonathan A Coleman
Journal: European Urology (2024)
A randomized controlled trial evaluated the efficacy and safety of apixaban for prevention of recurrent thrombosis after thrombectomy of hemodialysis vascular access.
Authors: Tsung-Yu Ko, Chih-Cheng Wu, Mu-Yang Hsieh, Chung-Wei Yang, Chi-Hung Cheng, Chun-Kai Chen, Hsien-Li Kao
Journal: Kidney International (2024)
Crosstalk Between Fibroblasts and Immune Cells in keloids
Authors: Junxian Wen, Yingrou Tan, Yong Yao Chun, Timothy T Y Tan, Hong Liang Tey
Journal: British Journal of Dermatology (2024)

Our letter in response to Min et al.’s study ‘Novel therapeutic strategy for intractable keloids: suppression of intracellular mechanotransduction and actin polymerization via Rho-kinase pathway inhibition’ highlights the importance of immune-cell interactions with mechanical forces in keloid pathogenesis. While the authors effectively demonstrate the potential of inhibiting mechanotransduction in fibroblasts, we underscore the critical role of immune cells, particularly their response to ECM stiffness, in modulating fibrosis and suggest this crosstalk may reveal additional therapeutic targets.
When I use a word . . . Academic fraud—the Darsee Affair
Authors: Jeffrey K Aronson
Journal: BMJ (2024)

Fraudulent academic activities that I have referred to as "felonies" comprise fabrication (defined by the US Office of Research Integrity as "making up data or results and recording or reporting them"), falsification ("manipulating research materials, equipment, or processes, or changing or omitting data or results such that the research is not accurately represented in the research record"), and plagiarism ("the appropriation of another person9s ideas, processes, results, or words without giving appropriate credit"). Many cases of fabrication and falsification reported in the 1970s increasingly drew attention to this, and none was perhaps more frequently referred to and discussed than the Darsee Affair, which involved extensive fabrication and falsification of research data by John R Darsee, working in Eugene Braunwald's laboratory in Boston. Several of Darsee's papers were subsequently retracted, but they continue to be cited as if they had not.
Exploring the driver events of eccrine poromas and porocarcinomas: A retrospective, cross-institutional study of 54 cases
Authors: Mark J Arends, Martin Del Castillo Velasco-Herrera, Saamin Cheema, Kim Wong, Jacqueline M Boccacino, Ian Vermes, Kirsty Roberts, Elizabeth Anderson, Michiel P J van der Horst, Nicolas de Saint Aubain, Ahmed K Alomari, Carlos Monteagudo, Steven D Billings, Derek Frew, Emily Clarke, William Merchant, Neil Rajan, Peter Ferguson, Carolin Mogler, Ingrid Ferreira, Thomas Brenn, Louise van der Weyden, David J Adams
Journal: British Journal of Dermatology (2024)

We have comprehensively characterised the mutational landscape of eccrine poroma (EP) and eccine porocarcinoma (EPC), uncovering novel events and delineating different pathways of tumorigenesis underlying these tumours. EPs are driven largely by oncogenic fusion genes, whereas EPCs are driven largely by somatic mutations affecting various pathways, with a subset driven by fusion genes as the first oncogenic driver, and somatic mutations representing secondary events contributing to progression of the tumour. Fusion genes in EP predominantly involve YAP1 whereas those in EPC preferentially involve PAK gene family members.
Interactive effect of genetic and environmental risk factors on Psoriasis: current evidence and future directives
Authors: Nidhi Singh, Tamara Schikowski
Journal: British Journal of Dermatology (2024)

Journal Article Accepted manuscript Interactive effect of genetic and environmental risk factors on Psoriasis: current evidence and future directives Get access Nidhi Singh, Nidhi Singh IUF-Leibniz Research Institute for Environmental Medicine, Düsseldorf, Germany Correspondence: Nidhi Singh, Email:nidhi.singh@iuf-duesseldorf.de https://orcid.org/0000-0002-4191-4189 Search for other works by this author on: Oxford Academic Google Scholar Tamara Schikowski Tamara Schikowski IUF-Leibniz Research Institute for Environmental Medicine, Düsseldorf, Germany https://orcid.org/0000-0002-4559-9374 Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, ljae450, https://doi.org/10.1093/bjd/ljae450 Published: 15 November 2024 Article history Received: 14 November 2024 Accepted: 14 November 2024 Published: 15 November 2024
Sex differences show responders to bevacizumab
Authors: Berta Segura-Collar, Sara Hiller-Vallina, Ricardo Gargini
Journal: Neuro-Oncology (2024)

Journal Article Corrected proof Sex differences show responders to bevacizumab Get access Berta Segura-Collar, Berta Segura-Collar Instituto de investigaciones Biomédicas I+12 (Imas12), Hospital 12 de Octubre, Madrid 28041, SpainPathology and Neurooncology Unit, Hospital Universitario 12 de Octubre, Madrid 28041, Spain Corresponding Author: Berta Segura-Collar, PhD, Pathology and Neurooncology Unit, Hospital Universitario 12 de Octubre, Av. de Córdoba, S/N, 28041 Madrid, Spain (bertasegura.imas12@h12o.es). https://orcid.org/0000-0001-8507-7434 Search for other works by this author on: Oxford Academic PubMed Google Scholar Sara Hiller-Vallina, Sara Hiller-Vallina Instituto de investigaciones Biomédicas I+12 (Imas12), Hospital 12 de Octubre, Madrid 28041, SpainPathology and Neurooncology Unit, Hospital Universitario 12 de Octubre, Madrid 28041, Spain Search for other works by this author on: Oxford Academic PubMed Google Scholar Ricardo Gargini Ricardo Gargini Instituto de investigaciones Biomédicas I+12 (Imas12), Hospital 12 de Octubre, Madrid 28041, SpainPathology and Neurooncology Unit, Hospital Universitario 12 de Octubre, Madrid 28041, Spain Corresponding Author: Ricardo Gargini, PhD, Pathology and Neurooncology Unit, Hospital Universitario 12 de Octubre, Av. de Córdoba, S/N, 28041 Madrid, Spain (ricgargini.imas12@h12o.es) https://orcid.org/0000-0003-4032-0095 Search for other works by this author on: Oxford Academic PubMed Google Scholar Neuro-Oncology, noae217, https://doi.org/10.1093/neuonc/noae217 Published: 15 November 2024 Article history Corrected and typeset: 15 November 2024 Published: 15 November 2024
Localised multiple spiradenomas are caused by somatic mosaicism in <i>ALPK1</i> hotspot mutation
Authors: Yui Hirano-Lotman, Yoshihiro Ishida, Hiromi Doi, Seishi Ogawa, Kenji Kabashima
Journal: British Journal of Dermatology (2024)

Spiradenocarcinomas, a rare skin adnexal tumour, are linked to the ALPK1 hotspot mutation. This study reveals that spiradenocarcinoma, accompanied by multiple localized spiradenomas, is caused by somatic mosaicism in the ALPK1 mutation hotspot.
Sixty seconds on . . . what not to say
Authors: Matthew Limb
Journal: BMJ (2024)

Thank you for your interest in spreading the word about The BMJ.NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * Your Email * Send To * You are going to email the following Sixty seconds on . . . what not to say Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Safety, efficacy and biomarker analysis of deulorlatinib (TGRX-326) in ALK-positive non-small-cell lung cancer: a multicentre, open-label, phase 1/1b trial
Authors: Shen Zhao, Huaqiang Zhou, Nong Yang, Zhehai Wang, Wenjian Jin, Yuxiang Ma, Jinhui Xue, Xingya Li, Yunpeng Liu, Rui Meng, Jianying Zhou, Ying Cheng, Yongsheng Wang, Zhuang Yu, Yu Cao, Yuanyuan Zhao, Yan Huang, Wenfeng Fang, Yang Zhang, Shaodong Hong, Bo Wu, Yanxia Shi, Jingrong Cao, Mingyan Xu, Xiaoni Zhang, Longyu Hu, Bo Peng, Yunpeng Yang, Li Zhang, Hongyun Zhao
Journal: Journal of Thoracic Oncology (2024)
A NIR-II Emissive Sonosensitized Biotuner for Pyroptosis-enhanced Sonodynamic Therapy of Hypoxic Tumors
Authors: Xiaoyu Wang, Weijie Chi, Jiao Wu, Jingwen Zou, Jiyoung Yoo, Seokjin Hong, Fan Zhang, Zhiqiang Mao, Jong Seung Kim
Journal: Biomaterials (2024)
Case-fatality rate of invasive pneumococcal disease caused by various serotypes - an analysis of nationwide surveillance data from Israel, 2009-2018
Authors: Anat Wieder-Finesod, Dafna Yahav, Carmit Rubin, Shirley Hashkor, Jo Southern, Gabriel Mircus, Christian Theilacker, Ron Dagan, Gili Regev-Yochay
Journal: Clinical Microbiology and Infection (2024)
Effectiveness of digital cognitive behavioral therapy for insomnia on professional activity: a systematic review and meta-analysis of randomized controlled trials
Authors: Dédrie Zettor, Francky Teddy Endomba, Achille Pierandrei, Jean-Michel Pinoit, Jean-Christophe Chauvet-Gelinier, Nathalie Forestier, Aymard Hussami
Journal: Sleep Medicine Reviews (2024)
Histamine Receptor Agonism Differentially Induces Immune and Reparative Healing Responses in Biomaterial-facilitated Tissue Repair
Authors: Jordan R Yaron, Shubham Pallod, Nicole Grigaitis-Esman, Vanshika Singh, Samantha Rhodes, Dirghau Manishbhai Patel, Deepanjan Ghosh, Kaushal Rege
Journal: Biomaterials (2024)
African swine fever virus in China: the diagnostic target gene (B646L) has acquired multi-point mutations
Authors: Lei-Lei Ding, Zhi-Gang Wang, Tian-Peng Wang, Zhen-Jiang Zhang, Feng-Wei Jiang, Lin-Fei Song, Kun Xue, Fang Li, Ren-Qiang Liu, Zhi-Gao Bu, Xiao-Dong Wu, En-Cheng Sun, Dong-Ming Zhao
Journal: Journal of Infection (2024)
Diagnosis and Management of Subungual and Periungual Verruca: A Clinical Review
Authors: Kaya L Curtis, Jeremy C Davis, Nilton Di Chiacchio, Nilton Gioia Di Chiacchio, Chander Grover, Matilde Iorizzo, Bianca Maria Piraccini, Michela Starace, Antonella Tosti, Shari R Lipner
Journal: Journal of the American Academy of Dermatology (2024)
Clinical Performance of a Noninvasive Melanoma Rule-Out Test Across Fitzpatrick Skin Types
Authors: Maral K Skelsey, Brent Loftis, Mark D Kaufmann, Daniel M Siegel, Neal Bhatia, Michael Wangia, Michael Walker, Andrew Rigby, John W Whitaker, Steven Stone, Mary Moccia, Kaleigh A O'Brien, Burkhard Jansen, Loren E Clarke
Journal: Journal of the American Academy of Dermatology (2024)
Retraction notice to “Acetylation of lactate dehydrogenase B drives NAFLD progression by impairing lactate clearance” [J Hepatol 74 (5) 2021 1038–1052]
Authors: Tongxin Wang, Kai Chen, Weilei Yao, Ruilong Zheng, Qiongyu He, Jun Xia, Juan Li, Yafei Shao, Li Zhang, Lu Huang, Longshan Qin, Mingming Xu, Zheng Zhang, Dingyu Pan, Zhen Li, Feiruo Huang
Journal: Journal of Hepatology (2024)
Trends in Peripheral Artery Disease, Lower Extremity Revascularization, and Lower Extremity Amputation in Incident Type 2 Diabetes: A Danish Population-Based Cohort Study
Authors: Christine Gyldenkerne, Kevin K.W. Olesen, Pernille G. Thrane, Malene K. Hansen, Nina Stødkilde-Jørgensen, Henrik T. Sørensen, Reimar W. Thomsen, Michael Maeng
Journal: Diabetes Care (2024)

OBJECTIVE To examine trends in peripheral artery disease (PAD), lower-extremity (LE) revascularization, and LE amputation in patients with incident type 2 diabetes. RESEARCH DESIGN AND METHODS This cohort study included patients in Denmark diagnosed with type 2 diabetes in 1996–2015 and followed until 2020. Patients were age and sex matched with as many as three general population individuals. Outcomes comprised 5-year cumulative incidences of first-time PAD, LE revascularization, and LE amputation. Age- and sex-adjusted hazard ratios (aHRs) were computed using Cox regression. RESULTS The cohort comprised 349,454 patients with incident type 2 diabetes (53% male; median age 62 years) and 1,025,054 general population individuals. Among patients with diabetes, decreases in 5-year cumulative incidence of PAD (from 6.2 to 3.4%; aHR 0.55 [95% CI 0.52–0.57]), LE revascularization (from 0.8 to 0.6%; aHR 0.80 [95% CI 0.71–0.90]), and LE amputation (from 1.0 to 0.4%; aHR 0.45 [95% CI 0.40–0.51]) occurred from 1996–2000 to 2011–2015. LE amputation decreased at all amputation levels (hip/thigh, knee/lower leg, and ankle/foot/toe) during the study period. In the general population, 5-year cumulative incidence remained stable (1.2–1.5% for PAD, ∼0.4% for LE revascularization, and ∼0.2% for LE amputation). However, the relative rates of all outcomes were two- to threefold higher in patients with diabetes than matched individuals in 2011–2015. CONCLUSIONS In recent decades, the cumulative incidence of LE complications substantially decreased in patients with incident type 2 diabetes while remaining stable in the general population.
MCRS1 sensitizes T cell–dependent immunotherapy by augmenting MHC-I expression in solid tumors
Authors: Xue Li, Han Yi, Zheyu Jin, Kaitao Jiang, Kangkang Xue, Jin Wang, Yuping Qian, Qian Xiang, Sijing Zhu, Runhe Yan, Yulong Yang, Shenfei Sun, Kai Li, Zichu Zhou, Wei Yu, Ning Jiang, Chen Ding, Xinhua Lin, Jiang Zhong, Yuchao Dong, Yanfang Liu, Xiaofei Yu
Journal: The Journal of Experimental Medicine (2024)

Dampened antigen presentation underscores the resistance of pancreatic cancer to T cell–mediated anti-tumor immunity, rendering immunotherapy largely ineffective. By high-throughput CRISPR activation perturbation, we discovered that the transcriptional regulator MCRS1 significantly augmented the sensitivity of mouse pancreatic cancer cells to T cell immunity in vitro and in vivo. Mechanistically, MCRS1 interacted with the transcription factor and genome organizer YY1 to coordinately increase the chromatin accessibility and expression of MHC-I genes. Elevated MCRS1 subverted MHC-I suppression and activated anti-tumor T cells, which sensitized mouse pancreatic cancer to α-PD-1 therapy. Remarkably, high MCRS1 expression was associated with increased T cell infiltration and extended survival of patients with pancreatic cancer and was predictive of favorable responses to α-PD-1 therapy in patients with lung cancer. Together, our study uncovers that MCRS1 sensitizes cancer cells to T cell immunity by transcriptionally subverting MHC-I suppression, which enhances the effectiveness of α-PD-1 therapy in mice and humans, paving the way to further improve immunotherapy against solid tumors.